Epidemiology, outcomes of treatment, and survival of cervical cancer in Kazakhstan: a nationwide population-based study
Aidana Rakhmankulova, Yesbolat Sakko, Abduzhappar Gaipov, Kuralay Atageldiyeva, Talshyn Ukybassova, Assem Suleimenova, Yerbolat Iztleuov, Gulzhanat Aimagambetova · 2026
Read Epidemiology, outcomes of treatment, and survival of cervical cancer in Kazakhstan: a nationwide population-based study by Aidana Rakhmankulova, Yesbolat Sakko, Abduzhappar Gaipov, Kuralay Atageldiyeva, Talshyn Ukybassova, Assem Suleimenova, Yerbolat Iztleuov, Gulzhanat Aimagambetova (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13278921.txt.
Description
Aidana Rakhmankulova and colleagues chart cervical cancer across Kazakhstan over a decade, in a 2026 nationwide study. HPV shots for girls began in 2024 in the country, so a pre-vaccine baseline matters. Registry data covered cases from 2014 to 2023.
Recorded cases climbed while incidence and death rates peaked around 2022. Five-year survival sat near sixty-five percent overall, with advanced-stage disease driving most lost years. Treatment with chemotherapy or radiation marked higher risk in adjusted models, reflecting more severe cases. Burden measures such as disability-adjusted life years also peaked in 2022. The authors offer the analysis as the benchmark for judging the years ahead.
Catalog record
| CREATOR | Aidana Rakhmankulova, Yesbolat Sakko, Abduzhappar Gaipov, Kuralay Atageldiyeva, Talshyn Ukybassova, Assem Suleimenova, Yerbolat Iztleuov, Gulzhanat Aimagambetova |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |